Last reviewed · How we verify
MFNS
MFNS is a progestin (megestrol acetate formulation) that acts as a synthetic progesterone receptor agonist to suppress appetite and promote weight gain in cachectic patients.
MFNS is a progestin (megestrol acetate formulation) that acts as a synthetic progesterone receptor agonist to suppress appetite and promote weight gain in cachectic patients. Used for Cancer cachexia and anorexia, Weight loss and appetite stimulation in advanced malignancy.
At a glance
| Generic name | MFNS |
|---|---|
| Also known as | SCH 32088, Nasonex |
| Sponsor | Organon and Co |
| Drug class | Progestin; appetite stimulant |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Palliative care |
| Phase | Phase 3 |
Mechanism of action
Megestrol acetate binds to progesterone receptors in the hypothalamus and other central nervous system regions, modulating appetite regulation and metabolic pathways. This leads to increased appetite stimulation and caloric intake, with secondary effects on lean body mass preservation and weight stabilization in patients with cancer cachexia or other wasting conditions.
Approved indications
- Cancer cachexia and anorexia
- Weight loss and appetite stimulation in advanced malignancy
Common side effects
- Thromboembolic events
- Hyperglycemia
- Adrenal suppression
- Vaginal bleeding
- Fluid retention
Key clinical trials
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (PHASE2)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
- Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (PHASE3)
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
- A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |